MX2009010878A - Pastilla de melatonina y metodos de preparacion y uso. - Google Patents
Pastilla de melatonina y metodos de preparacion y uso.Info
- Publication number
- MX2009010878A MX2009010878A MX2009010878A MX2009010878A MX2009010878A MX 2009010878 A MX2009010878 A MX 2009010878A MX 2009010878 A MX2009010878 A MX 2009010878A MX 2009010878 A MX2009010878 A MX 2009010878A MX 2009010878 A MX2009010878 A MX 2009010878A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- preparation
- pharmaceutically acceptable
- pharmaceutical composition
- melatonin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona una composición farmacéutica para administración sublingual o bucal de activos con solubilidad acuosa baja a pobre, por ejemplo, la melatonina de la hormona de indol, la cual contiene una solución del ingrediente activo en un solvente farmacéuticamente aceptable adsorbido o absorbido en las partículas de un portador farmacéuticamente aceptable y método de preparación y uso de la composición farmacéutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92292107P | 2007-04-11 | 2007-04-11 | |
PCT/US2008/004615 WO2008127609A1 (en) | 2007-04-11 | 2008-04-10 | Melatonin tablet and methods of preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009010878A true MX2009010878A (es) | 2010-03-26 |
Family
ID=39864239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010878A MX2009010878A (es) | 2007-04-11 | 2008-04-10 | Pastilla de melatonina y metodos de preparacion y uso. |
Country Status (11)
Country | Link |
---|---|
US (3) | US20100119601A1 (es) |
EP (2) | EP3056220A1 (es) |
JP (2) | JP5600058B2 (es) |
CN (1) | CN101677994B (es) |
AU (1) | AU2008239683B2 (es) |
CA (1) | CA2683436C (es) |
ES (1) | ES2575549T3 (es) |
IL (2) | IL201383A (es) |
MX (1) | MX2009010878A (es) |
RU (1) | RU2485949C2 (es) |
WO (1) | WO2008127609A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9254294B2 (en) | 2003-02-24 | 2016-02-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
US9358296B2 (en) | 2003-02-24 | 2016-06-07 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
US10172810B2 (en) * | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
MX2009010878A (es) * | 2007-04-11 | 2010-03-26 | John A Mccarty | Pastilla de melatonina y metodos de preparacion y uso. |
TR200907338A1 (tr) * | 2009-09-28 | 2011-04-21 | Yedi̇tepe Üni̇versi̇tesi̇ | Doğal bileşenler içeren bir film şeridi. |
AR084865A1 (es) | 2011-01-17 | 2013-07-10 | Takeda Pharmaceutical | Preparacion de desintegracion rapida, comprimido dispersable por via oral |
WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
TR201808978T4 (tr) | 2011-02-11 | 2018-07-23 | Zx Pharma Llc | Çok partiküllü l-mentol formülasyonları ve ilgili yöntemler. |
EP2570126B1 (en) | 2011-09-16 | 2014-03-26 | Darius Rassoulian | Use of melatonin for treating acute alcohol intoxication |
ITMI20112042A1 (it) * | 2011-11-10 | 2013-05-11 | Eratech S R L | Polvere da ricostituire prima dell'uso comprendente melatonina e preparazione iniettabile ottenibile da tale polvere. |
RU2488388C1 (ru) | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
UA107653U (uk) | 2012-10-01 | 2016-06-24 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів |
EP2919903B1 (en) | 2012-11-14 | 2020-07-22 | W.R. Grace & CO. - CONN. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
US20140303128A1 (en) * | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
WO2014175917A1 (en) | 2013-04-23 | 2014-10-30 | Zx Pharma, Llc | Multiparticulate-menthol formulations and related methods |
CA2992923C (en) * | 2014-07-21 | 2021-06-29 | Pharmaceutical Productions, Inc. | Solid dosage form composition for buccal and sublingual administration of cannabinoids |
CN105663061A (zh) * | 2014-11-16 | 2016-06-15 | 刘佳迪 | 褪黑素滴丸的制法和用法 |
NL2015272B1 (en) * | 2015-08-05 | 2017-05-02 | Versailles B V | Melatonin formulations and methods for preparation and use. |
WO2018167273A1 (en) * | 2017-03-16 | 2018-09-20 | Repoceuticals Aps | Compositions for retarding the decomposition of melatonin in solution |
US10806789B2 (en) * | 2017-05-12 | 2020-10-20 | The LIV Group Inc. | Composition for enhanced absorption of supplements |
US10500280B2 (en) | 2017-06-20 | 2019-12-10 | Physician's Seal, LLC | Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva |
WO2019038586A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | PHARMACEUTICAL COMPOSITION OF MELATONIN |
CN109953953B (zh) * | 2017-12-22 | 2021-09-21 | 深圳大学 | 一种褪黑素纳米缓释给药系统的制备方法 |
US20200078307A1 (en) | 2018-03-11 | 2020-03-12 | Nanologica Ab | Porous silica particles for use in a compressed pharmaceutical dosage form |
KR102506059B1 (ko) * | 2020-10-20 | 2023-03-07 | 코스맥스 주식회사 | 멜라토닌을 포함하는 항산화용 화장료 조성물 |
CN112426408B (zh) * | 2020-12-08 | 2023-12-19 | 广州帝奇医药技术有限公司 | 一种褪黑素组合物及其制备工艺 |
CN112870193B (zh) * | 2021-03-11 | 2022-07-08 | 大连医科大学附属第二医院 | 褪黑素在制备治疗对靶向药物耐药的her2阳性乳腺癌的药物中的应用 |
WO2023210811A1 (ja) * | 2022-04-28 | 2023-11-02 | 日本たばこ産業株式会社 | 無機多孔質材料を含む口腔用組成物 |
WO2023210813A1 (ja) * | 2022-04-28 | 2023-11-02 | 日本たばこ産業株式会社 | 無機多孔質材料を含む口腔用組成物 |
WO2023210814A1 (ja) * | 2022-04-28 | 2023-11-02 | 日本たばこ産業株式会社 | 無機多孔質材料を含む口腔用組成物 |
WO2023210812A1 (ja) * | 2022-04-28 | 2023-11-02 | 日本たばこ産業株式会社 | 多孔質材料を含む口腔用組成物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
US5073374A (en) * | 1988-11-30 | 1991-12-17 | Schering Corporation | Fast dissolving buccal tablet |
US4945103A (en) * | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
IT1243193B (it) | 1990-08-10 | 1994-05-24 | Medea Res Srl | Composizioni farmaceutiche orali a base di melatonina |
WO1995003043A1 (en) | 1993-07-26 | 1995-02-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Sustained release oral compositions containing melatonin |
US5767117A (en) * | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
US5688520A (en) | 1995-03-29 | 1997-11-18 | Minnesota Mining And Manufacturing Company | Transmucosal delivery of melatonin for prevention of migraine |
FR2742989B1 (fr) * | 1995-12-29 | 1998-01-23 | Adir | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs |
IL127955A0 (en) * | 1996-07-11 | 1999-11-30 | Farmarc Nederland Bv | Pharmaceutical composition containing acid addition salt of basic drug |
US6620836B1 (en) * | 1997-01-22 | 2003-09-16 | Jay Patrick | Antiarrhythmic and tranquilizer composition and treatment |
JP2001518923A (ja) | 1997-03-26 | 2001-10-16 | ダブリュ エイチ エム マーカス,フランシスカス | 鼻腔用メラトニン組成物 |
FR2762513B1 (fr) * | 1997-04-23 | 2003-08-22 | Permatec Pharma Ag | Comprimes bioadhesifs |
IT1298731B1 (it) | 1998-03-13 | 2000-02-02 | Recordati Chem Pharm | Composizioni farmaceutiche contenenti complessi di inclusione con melatonina |
JP4080686B2 (ja) * | 2000-11-06 | 2008-04-23 | 株式会社リコー | 画像形成装置 |
KR20010088917A (ko) * | 2001-07-30 | 2001-09-29 | 최종욱 | 디지털 정보 보안 방법 및 그 시스템 |
IL164163A0 (en) * | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
CN1210026C (zh) * | 2002-10-09 | 2005-07-13 | 重庆太极医药研究院 | 褪黑素双层控释片及制备工艺 |
EP2343045A3 (en) * | 2003-02-24 | 2011-09-21 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
EP1622587B1 (de) * | 2003-05-02 | 2010-04-28 | Globopharm Pharmazeutische Produktions- und Handelsgesellschaft m.b.H. | Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze |
MXPA06003813A (es) * | 2003-10-10 | 2006-06-14 | Lifecycle Pharma As | Forma solida de dosificacion que comprende un fibrato y una estatina. |
MY142989A (en) * | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
MX2009010878A (es) * | 2007-04-11 | 2010-03-26 | John A Mccarty | Pastilla de melatonina y metodos de preparacion y uso. |
US20140303227A1 (en) * | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
-
2008
- 2008-04-10 MX MX2009010878A patent/MX2009010878A/es active IP Right Grant
- 2008-04-10 JP JP2010503054A patent/JP5600058B2/ja active Active
- 2008-04-10 CA CA2683436A patent/CA2683436C/en active Active
- 2008-04-10 AU AU2008239683A patent/AU2008239683B2/en active Active
- 2008-04-10 EP EP16159279.5A patent/EP3056220A1/en not_active Ceased
- 2008-04-10 RU RU2009137472/15A patent/RU2485949C2/ru active
- 2008-04-10 EP EP08742710.0A patent/EP2144610B1/en active Active
- 2008-04-10 ES ES08742710.0T patent/ES2575549T3/es active Active
- 2008-04-10 WO PCT/US2008/004615 patent/WO2008127609A1/en active Application Filing
- 2008-04-10 CN CN200880019163.7A patent/CN101677994B/zh active Active
- 2008-04-10 US US12/595,183 patent/US20100119601A1/en not_active Abandoned
-
2009
- 2009-10-11 IL IL201383A patent/IL201383A/en active IP Right Grant
-
2012
- 2012-10-03 US US13/633,924 patent/US8992948B2/en active Active
-
2014
- 2014-08-12 JP JP2014164571A patent/JP2014237700A/ja not_active Ceased
-
2015
- 2015-02-27 US US14/634,689 patent/US9381190B2/en active Active
-
2016
- 2016-11-21 IL IL249102A patent/IL249102A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20100119601A1 (en) | 2010-05-13 |
IL201383A0 (en) | 2010-05-31 |
JP2014237700A (ja) | 2014-12-18 |
CA2683436A1 (en) | 2008-10-23 |
US9381190B2 (en) | 2016-07-05 |
IL249102A0 (en) | 2017-01-31 |
IL201383A (en) | 2017-01-31 |
CN101677994A (zh) | 2010-03-24 |
AU2008239683B2 (en) | 2014-03-27 |
US20150174101A1 (en) | 2015-06-25 |
EP3056220A1 (en) | 2016-08-17 |
CA2683436C (en) | 2016-07-26 |
EP2144610A1 (en) | 2010-01-20 |
EP2144610A4 (en) | 2013-08-07 |
EP2144610B1 (en) | 2016-04-06 |
JP2010523673A (ja) | 2010-07-15 |
JP5600058B2 (ja) | 2014-10-01 |
US20130028943A1 (en) | 2013-01-31 |
AU2008239683A1 (en) | 2008-10-23 |
CN101677994B (zh) | 2015-07-22 |
RU2485949C2 (ru) | 2013-06-27 |
ES2575549T3 (es) | 2016-06-29 |
WO2008127609A1 (en) | 2008-10-23 |
US8992948B2 (en) | 2015-03-31 |
RU2009137472A (ru) | 2011-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009010878A (es) | Pastilla de melatonina y metodos de preparacion y uso. | |
MX2013001989A (es) | Composicion que comprende compuestos tetraciclicos. | |
MX2020008616A (es) | Rocio de fentanilo sublingual. | |
MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
NZ599847A (en) | Pharmaceutical composition comprising a glp-1 agonist and methionine | |
WO2007008752A3 (en) | Sustained release pharmaceutical compositions for highly water soluble drugs | |
EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
MX369121B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
MY160728A (en) | Morpholinothiazoles as alpha 7 positive allosteric modulators | |
NZ707160A (en) | A stable aqueous composition comprising human insulin or an analogue or derivative thereof | |
NZ606123A (en) | Use of binders for manufacturing storage stable formulations | |
MY177027A (en) | Novel dosage and formulation | |
UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
MX2013006418A (es) | Derivados de oxazolil-metileter como agonistas del receptor de alx. | |
WO2011019326A3 (en) | Solubility and stability enchancing pharmaceutical formulation | |
PH12014501408A1 (en) | Immediate release multi unit pellet system | |
WO2011002422A3 (en) | Solubility enhancing pharmaceutical formulation | |
IL209270A (en) | Compounds containing tricyclic nitrogen and their use as antibacterial | |
IN2012DN00359A (es) | ||
MX2012007225A (es) | Composicion farmaceutica que comprende mezcla de solventes y derivado o analogo de vitamina d. | |
WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same | |
PH12014502407A1 (en) | New alfentanil composition for the treatment of acute pain | |
HK1120417A1 (en) | Stable nanoparticle formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: PHARMACEUTICAL PRODUCTIONS, INC. |
|
FG | Grant or registration |